Chemotherapy
The Use of Outpatient Parenteral Antimicrobial Therapy in the Management of Osteomyelitis: Data from the Outpatient Parenteral Antimicrobial Therapy Outcomes RegistriesTice A.University of Washington School of Medicine, Seattle, Wash., and Infections Limited/Stadium Way Consulting, Tacoma, Wash., USA
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: December 13, 2000
Issue release date: January – February
Number of Print Pages: 12
Number of Figures: 9
Number of Tables: 1
ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)
For additional information: https://www.karger.com/CHE
Abstract
Because osteomyelitis requires lengthy parenteral antibiotic treatment in patients who are often otherwise healthy, it lends itself well to outpatient parenteral antibiotic therapy (OPAT). Four delivery models for OPAT are (1) self-administration at home, (2) administration by a visiting nurse in the home, (3) infusion center and (4) nursing home. Patient selection is critical to the success of any OPAT program. Clinical and microbiologic data were compiled for more than 500 osteomyelitis patients reported in a registry of OPAT cases in the United States. The most commonly isolated pathogen was Staphylococcus aureus. The antibiotics used most frequently were vancomycin and ceftriaxone. Of 255 patients assessed for bacteriologic outcome, 2 patients developed infection with a new organism and 2 failed to eliminate the causative organism by the end of OPAT therapy. Of 266 patients who were assessed for clinical outcome, 259 improved and 7 failed. Data collected by the OPAT Outcomes Registry confirms that osteomyelitis can be safely and effectively treated with intravenous antibiotics outside the hospital.
© 1999 S. Karger AG, Basel
Related Articles:
References
-
Tice AD: Osteomyelitis. Hosp Pract 1993;28(suppl 2):36–39.
- Waldvogel FA, Medoff G, Swartz MN: Osteomyelitis: A review of clinical features, therapeutic considerations, and unusual aspects. N Engl J Med 1970;282:198–206
-
Gentry LO: Osteomyelitis. New York, Scientific American, 1998, vol 7, pp 1–7.
- Tice AD: Outpatient parenteral antimicrobial therapy for osteomyelitis. Infect Dis Clin North Am 1998;12:903–919.
- Lew DP, Waldvogel FA: Osteomyelitis. N Engl J Med 1997;336:999–1007.
-
Poretz DM: Infusion center, office, and home. Hosp Pract 1993;28 (suppl 2):40–43.
- Poretz DM: Home intravenous antibiotic therapy. Clin Geriatr Med 1991;7:749–763.
- Tice AD: Experience with a physician-directed, clinic-based program for outpatient parenteral antibiotic therapy in the USA. Eur J Clin Microbiol Infect Dis 1995;14:655–661.
-
Davey PG, Phillip G, Rowley D: Outpatient management of osteomyelitis. Infect Med 1994;11(suppl C):16–19.
-
Tice AD: Handbook of Outpatient Parenteral Therapy for Infectious Diseases. New York, Scientific American, 1997.
- Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner P: Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: A randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998;279:1537–1541.
-
Craig WA: Introduction. Eur J Clin Microbiol Infect Dis 1995;14:635.
- Zavasky D-M, Sande MA: Reconsideration of rifampin: A unique drug for a unique infection (editorial). JAMA 1998;279:1575–1577.
-
Tice AD: Outpatient parenteral antibiotic therapy (OPAT) in the United States: Delivery models and indications for use. Can J Infect Dis 2000;11(suppl A):17A–21A.
Article / Publication Details
Published online: December 13, 2000
Issue release date: January – February
Number of Print Pages: 12
Number of Figures: 9
Number of Tables: 1
ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)
For additional information: https://www.karger.com/CHE
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
PubMed ID
